DR30206 + irinotecan + leucovorin + fluorouracil

DR30206 + irinotecan + leucovorin + fluorouracil is a combination regimen under clinical investigation for the treatment of solid tumors, especially gastrointestinal cancers. DR30206 is an innovative trifunctional antibody fusion protein that targets three major cancer-associated pathways: PD-L1, VEGF, and TGF-β. Mechanistically, DR30206 is composed of the antibody bevacizumab (targeting VEGF), a variable domain of a heavy-chain antibody (VHH) directed against PD-L1, and the extracellular domain of TGF-β receptor II (TGF-β RII), fused to the N- and C-terminus of bevacizumab. Irinotecan is a topoisomerase I inhibitor, leucovorin is a folinic acid that enhances the efficacy of fluorouracil, and fluorouracil is an antimetabolite that inhibits thymidylate synthase. This multidrug combination is designed to synergistically inhibit multiple tumor growth and immunosuppressive pathways, aiming to improve antitumor efficacy compared to each agent alone or in smaller combinations. Early clinical trials are ongoing in gastrointestinal and other solid tumors[1].